ImmunoGen, Inc. Appoints Peter Williams as Vice President, Business Development

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the appointment of Peter Williams as Vice President, Business Development.

"Peter has played a lead role in a number of major transactions in the biotechnology sector,” commented Daniel Junius, President and Chief Executive Officer. "His experience establishing significant corporate collaborations while at Alnylam Pharmaceuticals and other successful organizations is directly relevant to ImmunoGen today. Peter brings considerable expertise in technology and product partnering and also in the oncology landscape that will complement the skill set of the rest of our management team. I am confident that Peter will have a substantial impact on our business development initiatives and in our maturation as a company.”

Mr. Williams brings to ImmunoGen over twenty years of business development, deal negotiation and technology in- and out-licensing experience. Prior to joining ImmunoGen, he was Senior Director of Business Development at Alnylam Pharmaceuticals, Inc., where he played a central role in the successful execution of large out-licensing and alliance transactions with global pharmaceutical companies. His positions prior to joining Alnylam include being Senior Director of Business Development at Millennium Pharmaceuticals, where he led several major alliances and transactions, and Associate Director, Office of Technology Licensing & Industry Sponsored Research, at Harvard Medical School, where he led activities related to commercializing in-house technology innovations. Mr. Williams has a Masters of Science degree in Management Science (accredited MBA) from the Imperial College of Science, Technology & Medicine, University of London, UK, and a Bachelors of Science degree in Biology from the University of Sussex, UK.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen’s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, T-DM1, is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.